Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Celestica is a strong company, with a remarkable and fortunate market position, but the valuation is now too high for strong ...

CoreWeave returned 170% in three months, but forward returns from the stock will likely be moderate, not negative. Learn more ...

This article was featured in One Great Story, New York’s reading recommendation newsletter. Sign up here to get it nightly.

So many fun events this week. Head out to Bristol for its Homecoming Festival, learn about the underground railroad or play in some foam in Mishawaka.

Since the city's establishment in the 1820s, Indianapolis has been a magnet for immigrants seeking opportunity and refuge.

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen.

Recruiters and lawyers in and outside government told BI that it's increasingly hard to move from public to private sector ...